Should Wave's New Obesity Data and INHBE/ALK7 Focus Require Action From Wave Life Sciences (WVE) Investors? [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
WVE-007, while senior leadership presented the story to investors at the J.P. Morgan Healthcare Conference. Investor attention has also focused on insider trading disclosures and new analyst coverage, alongside interest in the INHBE/ALK7 pathway and potential combinations of WVE-007 with existing obesity drugs. Next, we'll assess how Wave's fresh obesity data and INHBE/ALK7 pathway focus may influence the company's broader investment narrative. AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. To be a shareholder in Wave Life Sciences, you need to believe its RNA platforms, especially WVE-007 in obesity, can translate early biologic signals into successful late-stage programs despite ongoing losses and dilution risk. The latest roadmap and obesity data reinforce WVE-007 as the key near term catalyst, but they do not r
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing PortfolioGlobeNewswire
- WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=WVE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=WVE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
WVE
Earnings
- 11/10/25 - Miss
WVE
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 12/15/25 - Form SCHEDULE
- WVE's page on the SEC website